Back to Search
Start Over
Imatinib for the Treatment of Pulmonary Arterial Hypertension and Pulmonary Capillary Hemangiomatosis
- Source :
- Pulmonary Circulation. 4:342-345
- Publication Year :
- 2014
- Publisher :
- Wiley, 2014.
-
Abstract
- Despite currently available treatments, the prognoses of pulmonary arterial hypertension (PAH) and pulmonary capillary hemangiomatosis (PCH) remain poor. Platelet-derived growth factor and its receptor (PDGFR) have been implicated in the pathogenesis of pulmonary hypertension in PAH and PCH. Imatinib, a PDGFR antagonist, may be beneficial in the treatment of both conditions because of its potent antiproliferative effect. We report two cases that demonstrate the potential for safe and efficacious use of imatinib in PAH and PCH.
- Subjects :
- Pulmonary and Respiratory Medicine
biology
business.industry
Growth factor
medicine.medical_treatment
Antagonist
Case Report
Imatinib
Pulmonary capillary hemangiomatosis
Pharmacology
medicine.disease
Pulmonary hypertension
Pathogenesis
medicine
biology.protein
Receptor
business
neoplasms
Platelet-derived growth factor receptor
medicine.drug
Subjects
Details
- ISSN :
- 20458940
- Volume :
- 4
- Database :
- OpenAIRE
- Journal :
- Pulmonary Circulation
- Accession number :
- edsair.doi.dedup.....db48ea78c6a77c8133a65ff18e37a0c1